New York, Jan 12, 2026, 13:50 EST — Regular session
- Shares of Thermo Fisher fell roughly 1.8% in afternoon trading following the announcement of the COO and EVP departures
- Company also highlighted new AI-driven lab data and automation partnerships with TetraScience and Nvidia
- Investors are eyeing Tuesday’s J.P. Morgan Healthcare Conference presentation and the Jan. 29 earnings report for clues on demand
Shares of Thermo Fisher Scientific dropped Monday following a regulatory filing revealing that its chief operating officer plans to exit later this quarter amid a reshuffle of the company’s senior leadership. The stock slipped 1.8% to $607.56, cooling off from an earlier high of $624.14.
The management shake-up hits amid a hectic period for healthcare stocks, as investors seek clarity on biopharma budgets and lab equipment demand. Thermo Fisher, a key player in life-sciences tools, is pushing further into data and automation, areas that have been drawing steady interest throughout the sector.
Thermo Fisher revealed in a Form 8-K — the filing firms use to report major developments — that Michel Lagarde, the executive vice president and chief operating officer since 2021, is set to exit on March 31. The filing also showed that Frederick M. Lowery, an executive vice president since 2024, will step down on Feb. 28.
Starting March 1, the company will revamp its leadership and organizational setup. Marc N. Casper will step into the roles of chairman and chief executive officer. Gianluca Pettiti is set to move up as president and chief operating officer. Michael Shafer’s responsibilities will grow, with him now reporting straight to the CEO, according to the filing.
In a separate move, TetraScience announced a partnership with Thermo Fisher to advance “AI-native” scientific data and workflows in biopharma research and manufacturing. The goal: convert messy instrument outputs into standardized data that software can handle at scale. Sean Baumann, Thermo Fisher’s vice president for digital and AI in life sciences, diagnostics, and applied businesses, described “leveraging AI” as a natural next step in supporting lab work. 1
Nvidia revealed a new partnership with Thermo Fisher to develop “autonomous” lab infrastructure, merging AI with lab automation to conduct and analyze experiments with minimal manual input. Pettiti noted, “artificial intelligence coupled with laboratory automation will transform how scientific work is performed.” 2
Thermo Fisher’s drop coincided with declines across other life-sciences tools stocks. Danaher slid roughly 0.8%, while Agilent Technologies lost around 0.7% in afternoon trading.
Thermo Fisher is set to present Tuesday at the J.P. Morgan Healthcare Conference in San Francisco. This event is a key spot where firms typically outline early-year demand patterns and capital plans. 3
Thermo Fisher is set to unveil its quarterly results ahead of the market open on Jan. 29, covering both Q4 and the full year 2025. The company will host a conference call at 8:30 a.m. ET that day. 4
A major question remains: will leadership changes and the surge in AI-themed partnerships actually lead to more consistent orders in a sector known for volatility tied to biopharma funding shifts and client budgets? A cautious forecast later this month might overshadow the longer-term narrative.
Traders are set to focus on Casper’s comments Tuesday regarding demand, margins, and the speed of automation and data investments — then await concrete figures and guidance on Jan. 29.
